SAN DIEGO, Dec. 8, 2010 /PRNewswire/ — Otonomy, Inc.
announced today that David A.
Weber, Ph.D., has joined the company as president, CEO and
member of the Board of Directors. Jay Lichter, Ph.D., managing
director of Avalon Ventures, co-founder of Otonomy and CEO since
its inception, will continue to actively support the company as a
member of the Board of Directors.

“We are very pleased to welcome Dr. Weber to the Otonomy team,
as his extensive experience in the development of locally delivered
therapeutics is highly transferrable to our focus on local
treatments for disorders of the inner and middle ear,” said Jay
Lichter, Ph.D., managing director of Avalon Ventures and co-founder
of Otonomy. “His excellent credibility in the venture capital
community and proven success in strategic partnering will be
essential skills in leading Otonomy forward following our
successful recent Series B financing.”

Dr. Weber has spent over 20 years in the life sciences field
and, for the last decade, has led companies developing locally
delivered therapeutics. Dr. Weber is currently an independent
director of On Demand Therapeutics, Inc., where he provides
guidance on business development, financing and product development
strategy. He was the founding CEO of MacuSight, a venture-backed
start-up focused on local treatments for ocular disorders. There he
successfully built the team, completed a strategic transaction that
generated $50 million in upfront payments and advanced the
development program through decisive clinical studies in several
areas. Prior to that, Dr. Weber was acting CEO of Oculex
Pharmaceuticals, where he led the company through its successful
acquisition by Allergan. As executive vice president, research and
development at Oculex, Dr. Weber was responsible for the
advancement of a sustained release ster

‘/>”/>

SOURCE